Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

Delayed Quote. Delayed  - 07/22 09:56:23 pm
0.6404 USD   -1.48%
07/07 Protalix BioTherapeutics Announces First Patient Dosed in the AIR..
06/06 Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clini..
06/02 Protalix BioTherapeutics to Present at the Jefferies 2016 Global ..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
07/18/2016 07/19/2016 07/20/2016 07/21/2016 07/22/2016 Date
0.64(c) 0.645(c) 0.6597(c) 0.65(c) 0.6404(c) Last
31 529 13 475 39 304 36 356 249 286 Volume
-1.54% +0.78% +2.28% -1.47% -1.48% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 4,06x
Capi. / Sales2014 1,79x
Capitalization 63,9 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
07/21 PROTALIX BIOTHERAPEUTICS : Findings from Y. Tekoah et al in Plant Biotechnology ..
07/07 PROTALIX BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits..
07/07 Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase&trade..
06/07 PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements ..
06/06 PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
06/06 Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of..
06/02 Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare C..
05/09 PROTALIX BIOTHERAPEUTICS : reports 1Q loss
05/09 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
05/09 Protalix BioTherapeutics Reports First Quarter 2016 Financial Results and Pro..
More news
Sector news : Biotechnology & Medical Research - NEC
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 894%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTI..-37.22%64
INCYTE CORPORATION-20.32%16 212
CELLTRION, INC.--.--%10 689
LONZA GROUP AG11.40%9 737
QUINTILES TRANSNATIONA..7.82%8 859
ALKERMES PLC-37.26%7 528
More Results